These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Title of each class of securities to which transaction applies:
|
|
|
(2) Aggregate number of securities to which transaction applies:
|
|
|
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4) Proposed maximum aggregate value of transaction:
|
|
|
(5) Total fee paid:
|
|
o
|
Fee paid previously with preliminary materials.
|
|
o
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
1.
|
Elect the two directors named in the attached Proxy Statement, each for a term of three years;
|
|
|
2.
|
Ratify the appointment of PricewaterhouseCoopers LLP as Ormat Technologies, Inc.’s independent registered public accounting firm for the year ending December 31, 2013; and
|
|
|
3.
|
Transact any other business that may properly come before the meeting or any postponements or adjournments of the meeting.
|
|
By order of the Board of Directors,
|
|
|
/s/ Yehudit Bronicki
Yehudit Bronicki
Chief Executive Officer
|
|
|
·
|
This Proxy Statement, the proxy card form, the Notice of Internet Availability of Proxy Materials and our Annual Report on Form 10-K are available at
http://materials.proxyvote.com/686688
by clicking on the proxy link.
|
|
|
·
|
You will need your assigned control number to vote your shares. Your control number can be found on your proxy card or voting instruction form.
|
|
|
·
|
The time and location of the Annual Meeting of Stockholders are noted above.
|
|
1
|
|
|
2
|
|
|
5
|
|
|
6
|
|
|
6
|
|
|
8
|
|
|
9
|
|
|
9
|
|
|
11
|
|
|
11
|
|
|
12
|
|
|
12
|
|
|
12
|
|
|
12
|
|
|
13
|
|
|
15
|
|
|
17
|
|
|
19
|
|
|
20
|
|
|
24
|
|
|
25
|
|
|
25
|
|
|
27
|
|
|
29
|
|
|
30
|
|
|
30
|
|
|
32
|
|
|
33
|
|
|
34
|
|
34
|
|
|
39
|
|
|
40
|
|
|
40
|
|
|
40
|
|
|
40
|
|
|
42
|
|
|
42
|
|
|
42
|
|
|
42
|
|
|
42
|
|
|
43
|
|
|
·
|
vote by internet or by telephone and how you can receive a paper or email copy of a proxy card if you are a record holder of shares; or
|
|
|
·
|
give voting instructions to your bank or brokerage firm if your shares are held in street name.
|
|
|
● by signing and delivering another proxy with a later date;
|
|
|
● by giving written notice of such revocation to the Corporate Secretary of Ormat prior to or at the meeting; or
|
|
|
● by voting in person at the meeting.
|
|
|
●
|
The election of the two nominees named in this proxy statement to the Board of Directors; and
|
|
●
|
The ratification of PricewaterhouseCoopers LLP as Ormat’s independent registered public accounting firm for the year ending December 31, 2013.
|
|
|
Class III Directors (term expiring upon the annual stockholders meeting in 2013)
|
|
|
Gillon Beck
|
|
|
Dan Falk
|
|
|
Class I Directors (term expiring upon the annual stockholders meeting in 2014)
|
|
|
Yoram Bronicki
|
|
|
David Granot
|
|
|
Robert E. Joyal
|
|
|
Class II Directors (term expiring upon the annual stockholders meeting in 2015)
|
|
|
Yehudit Bronicki
|
|
|
Robert F. Clarke
Ami Boehm
|
|
|
·
|
making recommendations to the Board as to changes in Ormat’s general compensation philosophy;
|
|
|
·
|
overseeing the development and implementation of compensation programs;
|
|
|
·
|
reviewing and approving corporate goals and objectives relevant to the compensation of the CEO, and evaluating the performance of the CEO in light of those goals and objectives; and
|
|
|
·
|
reviewing and approving the annual compensation of the CEO and Ormat’s five other most highly compensated executive officers who receive total compensation in excess of $1 million per year.
|
|
Dan Falk, Chair
Robert F. Clarke
David Granot
Robert E. Joyal
|
|
Name
|
Age
|
Position
|
||
|
Yehudit Bronicki
|
71 |
Chief Executive Officer and Director
|
||
|
Lucien Bronicki
|
78 |
Chief Technology Officer
|
||
|
Yoram Bronicki
|
46 |
President, Chief Operating Officer and Director
|
||
|
Joseph Tenne†
|
57 |
Chief Financial Officer
*
|
||
|
Doron Blachar†
|
45 |
Chief Financial Officer
*
|
||
|
Nadav Amir
|
62 |
Executive Vice President—Operations
*
|
||
|
Zvi Reiss
|
62 |
Executive Vice President—Project Management
*
|
||
|
Shimon Hatzir
|
51 |
Senior Vice President—Engineering
*
|
||
|
Zvi Krieger
|
57 |
Executive Vice President—Geothermal Resource
*
|
||
|
Etty Rosner
|
57 |
Senior Vice President—Contract Management; Corporate Secretary
*
|
||
|
Nir Wolf
|
47 |
Vice President—Business Development — Marketing and Sales, Rest of the World
*
|
|
*
|
Performs the functions described in the table, but is employed by Ormat Systems Ltd., a subsidiary of the Company.
|
|
†
|
Mr. Doron Blachar will replace Mr. Tenne as the Company's CFO, effective April 2, 2013.
|
|
|
● each person, or group of affiliated persons, known to us to own beneficially 5% or more of our outstanding Common Stock;
|
|
|
● each of our directors;
|
|
|
● each of our Named Executive Officers (as defined under Compensation Discussion and Analysis below); and
|
|
|
● all of our directors and executive officers as a group.
|
|
Shares of
Ormat Technologies, Inc.
Common Stock
Beneficially Owned
|
Shares of
Ormat Industries Ltd.
Common Stock
Beneficially Owned
|
|||||||||||||||
|
Number
|
Percent
|
Number
|
Percent
|
|||||||||||||
|
Principal Stockholder:
|
||||||||||||||||
|
Ormat Industries Ltd.
†
|
27,206,580 | (1) | 59.89 | % | ||||||||||||
|
Clal Insurance Enterprises Holdings Ltd.
‡
|
3,044,513 | 6.7 | % | |||||||||||||
|
Directors and Named Executive Officers
|
||||||||||||||||
|
Yehudit Bronicki
†
|
— | — | 25,712,072 | (2) | 22.07 | % | ||||||||||
|
Lucien Bronicki
†
|
— | — | 25,712,072 | (2) | 22.07 | % | ||||||||||
|
Yoram Bronicki
†
|
— | — | 25,712,072 | (2) | 22.07 | % | ||||||||||
|
Gillon Beck
††
|
— | — | 26,218,049 | (3) | 22.50 | % | ||||||||||
|
Ami Boehm
††
|
— | — | 26,218,049 | (3) | 22.50 | % | ||||||||||
|
Dan Falk
††
|
45,000 | (4) | * | — | — | |||||||||||
|
Robert F. Clarke
††
|
47,000 | (5) | * | — | — | |||||||||||
|
David Granot
††
|
— | — |
__
|
__
|
||||||||||||
|
Robert E. Joyal
††
|
— | — |
__
|
__
|
||||||||||||
|
Joseph Tenne
†
|
92,900 | * | — | — | ||||||||||||
|
Nadav Amir
†
|
111,200 | * | — | — | ||||||||||||
|
Zvi Reiss
†
|
111,200 | * | — | — | ||||||||||||
|
Shimon Hatzir
|
76,250 | * | — | — | ||||||||||||
|
Directors and Named Executive Officers as a group
|
558,550 | (6) | * | 51,930,121 | 44.57 | % | ||||||||||
|
† c/o Ormat Industries Ltd., Industrial Area, P.O. Box 68 Yavne 81100, Israel
|
|
†† c/o Ormat Technologies, Inc., 6225 Neil Road, Reno, Nevada 89511
|
|
‡
|
48 Menachem Begin Road, Tel Aviv 66180, Israel. The information provided for Clal Insurance Enterprises Holdings Ltd. ("Clal") is based on Clal's Schedule 13G/A filed with the SEC on February 14, 2013. Clal reported shared voting and dispositive power with regard to all of the 3,044,513 shares beneficially held by Clal.
|
|
* Represents beneficial ownership of less than 1% of the outstanding shares of Common Stock.
|
|
(1)
|
The Board of Directors of Ormat Industries Ltd. has voting power and investment power over approximately 59.89% of our outstanding Common Stock. The directors of Ormat Industries Ltd. include Lucien Bronicki, Yehudit Bronicki and Yoram Bronicki, who, collectively with other members of their family, beneficially owned approximately 22.07% of the ordinary shares of Ormat Industries Ltd. through their holdings in Bronicki Investment Ltd. as of March 18, 2013. FIMI ENRG Limited Partnership and FIMI ENRG L.P., both of which are controlled by FIMI Opportunity IV L.P., currently have voting power and investment power over approximately 22.5% of the ordinary shares of Ormat Industries Ltd. as of March 18, 2013. Gillon Beck, a partner of FIMI Opportunity Funds, also serves as a director of Ormat Industries Ltd.
|
|
(2)
|
These shares are beneficially owned by Bronicki Investment Ltd. Lucien Bronicki and Yehudit Bronicki are directors of Bronicki Investment Ltd. and have voting control of the shares of Ormat Industries Ltd. held by Bronicki Investment Ltd. Each of Lucien Bronicki, Yehudit Bronicki and Yoram Bronicki also beneficially own 20% of Bronicki Investment Ltd. Accordingly, they may be deemed to share beneficial ownership of the shares of Ormat Industries Ltd. held by Bronicki Investment Ltd. Each of Lucien Bronicki, Yehudit Bronicki and Yoram Bronicki disclaim beneficial ownership of all such shares, except to the extent of his or her 20% ownership of Bronicki Investment Ltd.
|
|
(3)
|
These shares are beneficially owned by FIMI Opportunity Funds. Gillon Beck and Ami Boehm are partners of FIMI Opportunity Funds and have voting control of the shares of Ormat Industries Ltd. held by FIMI Opportunity Funds. Accordingly, they may be deemed to share beneficial ownership of the shares of Ormat Industries Ltd. held by FIMI Opportunity Funds. Each of Gillon Beck and Ami Boehm disclaim beneficial ownership of all such shares. FIMI Opportunity Funds pledged all of its Ordinary Shares of Ormat Industries Ltd. in favor of Bank Hapoalim BM as collateral for Bronicki Investment Ltd.'s 2007 loan from Bank Hapoalim.
|
|
(4)
|
Includes 45,000 shares of Common Stock issuable to Mr. Falk upon the exercise of options that are exercisable within 60 days of March 18, 2013.
|
|
(5)
|
Includes 45,000 shares of Common Stock issuable to Mr. Clarke upon the exercise of options that are exercisable within 60 days of March 18, 2013.
|
|
(6)
|
This number includes options of the Company exercisable within 60 days of March 18, 2013. The amounts of exercisable options for each named Executive Officer are set forth in the Outstanding Equity Awards Table below.
|
|
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options, Warrants
and Rights
|
Weighted Average
Exercise Price of
Outstanding Options,
Warrants and Rights
|
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation Plans
|
||||||||||
|
Equity Compensation plans approved
by security holders
|
3,555,740
|
* | $ | 30.19 | 3,925,000 | † | ||||||
|
Equity Compensation plans not approved by security holders
|
-- | N/A | -- | |||||||||
|
Total
|
3,555,740 | * | $ | 30.19 | 3,925,000 | † | ||||||
|
*
|
Stock options to be issued pursuant to our 2004 Incentive Compensation Plan, as amended, and our 2012 Incentive Compensation Plan, and our Registration Statement on Form S-8 covering 1,250,000 shares filed with the SEC on November 9, 2005, and our Registration Statement on Form S-8 covering 2,500,000 shares filed with the SEC on June 4, 2007, and our Registration Statement on Form S-8 covering 4,000,000 shares filed with the SEC on May 18, 2012.
|
|
†
|
On May 8, 2012, at the Company’s 2012 annual meeting of shareholders, the Company’s shareholders approved the Ormat Technologies, Inc. 2012 Incentive Compensation Plan (the “2012 Plan”), which the Board of Directors of the Company had approved on March 20, 2012. No further awards will be granted under the 2004 Incentive Compensation Plan. On May 18, 2012, the Company filed a post-effective Amendment No. 1 to Form S-8 whereby the Company removed from registration 51,149 unissued shares that had remained available for grant under the 2004 Incentive Compensation Plan, as amended.
|
|
|
1.
|
Annual salary, which is paid bi-monthly, is intended to provide an annual income at a level consistent with individual contributions.
|
|
|
2.
|
Annual bonuses, which are paid semi-annually for our Group II executives, are intended to link our executive officers’ compensation to their individual achievements as well as the Company’s overall performance.
|
|
|
3.
|
Equity awards are designed to promote long-term leadership and align the interests of our executives in Group II with those of our stockholders, while the vesting schedule assists us in retaining our executives in our employ. Equity awards begin to vest following two years from the date of grant, with 25% vesting on each of the second and third anniversaries of the date of grant and the remaining 50% on the fourth anniversary of the date of grant. All employees and consultants of the Company are eligible to receive equity awards pursuant to the Company's incentive compensation plan; however, our Group I executives do not receive equity awards. The term of our equity awards ranges from seven to ten years from the date of grant; there is no provision that provides for accelerated vesting upon a change in control; and there is no holding period for vested options.
|
|
|
Each element is determined individually, based on the relevant criteria described in this discussion.
|
|
Yehudit Bronicki, Chair
Dan Falk
Ami Boehm
|
|
Name and Principal Position
|
Year
|
Salary($)
|
Bonus ($)
|
Option
Awards
($) (2)
|
All Other
Compens ation
($)
|
Total ($)
|
||||||||||||||||
|
Lucien Y. Bronicki, Chief Technology
|
||||||||||||||||||||||
|
Officer
|
2012
|
124,000 | ---- |
None
|
49,230 | ( 3 ) | 173,230 | |||||||||||||||
|
2011
|
124,000 | ---- |
None
|
54,652 | 178,652 | |||||||||||||||||
|
2010
|
124,000 | 264,210 | ( 1 ) |
None
|
53,661 | 441,871 | ||||||||||||||||
|
Yehudit Bronicki, Chief Executive Officer,
|
||||||||||||||||||||||
|
and Director
|
2012
|
150,000 | ---- |
None
|
62,025 | ( 4 ) | 212,025 | |||||||||||||||
|
2011
|
150,000 | ---- |
None
|
74,936 | 224,936 | |||||||||||||||||
|
2010
|
150,000 | 264,210 | ( 1 ) |
None
|
69,254 | 483,464 | ||||||||||||||||
|
Yoram Bronicki, President, Chief Operating
|
||||||||||||||||||||||
|
Officer and Director
|
2012
|
168,000 | ---- |
None
|
78,472 | ( 5 ) | 246,472 | |||||||||||||||
|
2011
|
168,000 | ---- |
None
|
81,080 | 249,080 | |||||||||||||||||
|
2010
|
168,000 | 264,210 | ( 1 ) |
None
|
78,516 | 510,726 | ||||||||||||||||
|
Joseph Tenne, Chief Financial
|
||||||||||||||||||||||
|
Officer
|
2012
|
259,479 | ---- | 175,560 | 83,894 | ( 6 ) | 518,933 | |||||||||||||||
|
2011
|
290,429 | 9,946 | 235,680 | 94,201 | 630,256 | |||||||||||||||||
|
2010
|
204,936 | 87,666 | 303,360 | 73,279 | 678,452 | |||||||||||||||||
|
Nadav Amir, Executive Vice President -
|
||||||||||||||||||||||
|
Operations
|
2012
|
263,901 | ---- | 175,560 | 77,380 | ( 7 ) | 516,841 | |||||||||||||||
|
2011
|
278,498 | 55,412 | 235,680 | 80,635 | 650,225 | |||||||||||||||||
|
2010
|
256,929 | 87,666 | 303,360 | 77,836 | 725,791 | |||||||||||||||||
|
Zvi Reis s , Executive Vice President -
|
||||||||||||||||||||||
|
Cons truction Management
|
2012
|
208,789 | ---- | 235,680 | 59,865 | ( 8 ) | 504,334 | |||||||||||||||
|
2011
|
279,034 | 7,700 | 235,680 | 78,362 | 600,776 | |||||||||||||||||
|
2010
|
275,923 | 17,387 | 303,360 | 73,630 | 670,300 | |||||||||||||||||
|
Shimon Hatzir, Senior Vice President
|
||||||||||||||||||||||
|
Engineering
|
2012
|
198,114 | ---- | 175,560 | 69,052 | ( 9 ) | 442,726 | |||||||||||||||
|
2011
|
206,476 | 55,412 | 235,680 | 76,110 | 573,678 | |||||||||||||||||
|
2010
|
190,215 | 87,666 | 303,360 | 61,366 | 642,607 | |||||||||||||||||
|
(1)
|
Represents annual bonus for each of Mr. Lucien Bronicki, Mrs. Yehudit Bronicki, and Mr. Yoram Bronicki from the Company, based on formulas set forth in their employment agreements, which are described below.
|
|
(2)
|
Represents the grant date fair value in accordance with accounting guidance for stock compensation. The awards were Stock Appreciation Rights (SARs). Each NEO is entitled to receive shares of Common Stock equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised. For a discussion of the assumptions used in reaching this valuation, see Note 15 to our consolidated financial statements included in our annual report on Form 10-K for the year ended December 31, 2011.
|
|
(3)
|
Includes payments of auto-related expenses in the amount of $10,669; Israel National Insurance in the amount of $1,093; health insurance in the amount of $214; convalescence pay in the amount of $1,564; Defined Contribution Plan in the amount of $19,522; Education Fund in the amount of $2,212; vacation redemption of $12,400; and perquisites amounting to $1,556.
|
|
(4)
|
Includes payments of auto-related expenses in the amount of $10,669; Israel National Insurance in the amount of $953; U.S. Social Security in the amount of $5,106; health insurance in the amount of $214; convalescence pay in the amount of $1,564; Defined Contribution Plan in the amount of $20,961; Education Fund in the amount of $2,212; vacation redemption of $18,947; and perquisites amounting to $1,399.
|
|
(5)
|
Includes payments of auto-related expenses in the amount of $13,345; Israel National Insurance in the amount of $7,208; U.S. Social Security in the amount of $3,581; health insurance in the amount of $14,407; convalescence pay in the amount of $1,564; 401(k) Plan matching contribution in the amount of $3,500; Defined Contribution Plan in the amount of $18,839; Education Fund in the amount of $2,212; vacation redemption of $11,177; and perquisites amounting to $2,639.
|
|
(6)
|
Includes payments of auto-related expenses in the amount of $13,830; Israel National Insurance in the amount of $7,329; U.S. Social Security in the amount of $1,837; health insurance in the amount of $214; convalescence pay in the amount of $1,564; Defined Contribution Plan in the amount of $34,103; Education Fund in the amount of $3,687; vacation redemption of $18,638; and perquisites amounting to $2,692.
|
|
(7)
|
Includes payments of auto-related expenses in the amount of $13,266; Israel National Insurance in the amount of $7,329; health insurance in the amount of $214; convalescence pay in the amount of $1,564; Defined Contribution Plan in the amount of $41,522; Education Fund in the amount of $3,687; vacation redemption of $7,859; and perquisites amounting to $1,939.
|
|
(8)
|
Includes payments of auto-related expenses in the amount of $14,580; Israel National Insurance in the amount of $7,329; health insurance in the amount of $49; convalescence pay in the amount of $1,564; Defined Contribution Plan in the amount of $31,810; Education Fund in the amount of $3,687; and perquisites amounting to $846.
|
|
(9)
|
Includes payments of auto-related expenses in the amount of $13,329; Israel National Insurance in the amount of $7,329; convalescence pay in the amount of $1,564; Defined Contribution Plan in the amount of $28,388; Education Fund in the amount of $3,687; vacation redemption of $13,283; and perquisites amounting to $1,472.
|
|
Name
|
Grant Date
|
All Other Option Awards : Number of
Securities Underlying
Options (1)
|
Exercise Price of Option Awards
($/Sh)
|
Grant Date Fair Value of Option Awards ($)
(2)
|
||||||||||
|
Lucien Y. Bronicki
|
None
|
None
|
N/A | N/A | ||||||||||
|
Yehudit Bronicki
|
None
|
None
|
N/A | N/A | ||||||||||
|
Yoram Bronicki
|
None
|
None
|
N/A | N/A | ||||||||||
|
Joseph Tenne
|
April 2, 2012
|
22,000 | 20.13 | 175,560 | ||||||||||
|
Nadav Amir
|
April 2, 2012
|
22,000 | 20.13 | 175,560 | ||||||||||
|
Zvi Reiss
|
April 2, 2012
|
22,000 | 20.13 | 175,560 | ||||||||||
|
Shimon Hatzir
|
April 2, 2012
|
22,000 | 20.13 | 175,560 | ||||||||||
|
(1)
|
These grants were Stock Appreciation Rights (SARs), and each NEO is entitled to receive shares of Common Stock equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised. These SARs begin to vest following two years from the date of grant (April 2012), with 25% of the SARs vesting on each of the second and third anniversaries of the grant date and the remaining 50% on the fourth anniversary of the grant date. The SARs will become completely exercisable in April 2016.
|
|
(2)
|
These amounts are the grant date fair value of each award, computed in accordance with accounting guidance for stock compensation.
|
|
Option Awards
|
|||||||||||
|
Name
|
Number of Securities Underlying Unexercised Options
(#) Exercisable
|
Number of Securities Underlying Unexercised Options
(#) Unexercisable
|
Option
Exercise
Price ($)
|
Option Expiration Date
|
|||||||
|
Lucien Y. Bronicki
|
None
|
None
|
N/A | N/A | |||||||
|
Yehudit Bronicki
|
None
|
None
|
N/A | N/A | |||||||
|
Yoram Bronicki
|
None
|
None
|
N/A | N/A | |||||||
|
Joseph Tenne
|
14,900
20,000
20,000
13,000
6,000
None
None
|
None
None
None
13,000 (1)
18,000 (2)
24,000 (3)
22,000 (4)
|
34.13
42.08
45.78
26.84
29.95
25.65
20.13
|
April 7, 2016
March 29, 2014
April 8, 2015
March 18, 2016
April 16, 2017
March 31, 2018
April 2, 2019
|
|||||||
|
Nadav Amir
|
20,000
24,000
24,000
15,600
6,000
None
None
|
None
None
None
15,600 (2)
18,000 (2)
24,000 (3)
22,000 (4)
|
34.13
42.08
45.78
26.84
29.95
25.65
20.13
|
April 7, 2016
March 29, 2014
April 8, 2015
March 18, 2016
April 16, 2017
March 31, 2018
April 2, 2019
|
|||||||
|
Zvi Reiss
|
20,000
24,000
24,000
15,600
6,000
None
None
|
None
None
None
15,600 (2)
18,000 (2)
24,000 (3)
22,000 (4)
|
34.13
42.08
45.78
26.84
29.95
25.65
20.13
|
April 7, 2016
March 29, 2014
April 8, 2015
March 18, 2016
April 16, 2017
March 31, 2018
April 2, 2019
|
|||||||
|
Shimon Hatzir
|
9,000
15,000
17,500
11,374
6,000
None
None
|
None
None
None
11,376 (2)
18,000 (2)
24,000 (3)
22,000 (4)
|
34.13
42.08
45.78
26.84
29.95
25.65
20.13
|
April 7, 2016
March 29, 2014
April 8, 2015
March 18, 2016
April 16, 2017
March 31, 2018
April 2, 2019
|
|||||||
|
(1)
|
These are SARs which began to vest two years after the March 2009 grant date, with 25% of the SARs vesting on each of the second and third anniversaries of the grant date, and the remaining 50% on the fourth anniversary of the grant date. The SARs will become completely exercisable in March 2013. Each NEO is entitled to receive shares of Common Stock equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
|
(2)
|
These are SARs which began to vest two years after the April 2010 grant date, with 25% of the SARs vesting on each of the second and third anniversaries of the grant date, and the remaining 50% on the fourth anniversary of the grant date. The SARs will become completely exercisable in April 2014. Each NEO is entitled to receive shares of Common Stock equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
|
(3)
|
These are SARs which begin to vest two years
after the March 2011 grant date, with 25% of the SARs vesting on each of the second and third anniversaries of the grant date, and the remaining 50% on the fourth anniversary of the grant date. The SARs will become completely exercisable in March 2015. Each NEO is entitled to receive shares of Common Stock equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
|
(4)
|
These are SARs which begin to vest two years
after the April 2012 grant date, with 25% of the SARs vesting on each of the second and third anniversaries of the grant date, and the remaining 50% on the fourth anniversary of the grant date. The SARs will become completely exercisable in April 2016. Each NEO is entitled to receive shares of Common Stock equal to the amount by which the market value of the shares in respect of which the SAR is exercised exceeds the grant price set forth in the SAR, multiplied by the number of shares in respect of which the SAR is exercised.
|
|
●
|
any person holds or becomes the holder of 50% or more of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors of the Company or of Ormat Industries, excluding any acquisition directly from the Company or from Ormat Industries or any acquisition by the Company;
|
|
●
|
more than 50% of the current members of the Board of Directors or directors nominated by the current members of the Board no longer serve as directors;
|
|
●
|
the Company merges or is consolidated with, or, in any transaction or series of transactions, substantially all of the business or assets of the Company are sold or otherwise acquired by, another corporation or entity; or
|
|
●
|
the stockholders of the Company or of Ormat Industries approve a complete liquidation or dissolution of the Company or Ormat Industries.
|
|
|
“Good reason” means:
|
|
●
|
a reduction by the Company in the respective executive officer’s base salary or bonus as in effect at the time of a change in control, or a change in the manner of computation of such officer’s bonus that is adverse to him or her;
|
|
●
|
the assignment to the respective executive officer of any duties inconsistent with his or her position, duties, responsibilities and status with the Company at the time of the change in control, or any material reduction in authority or responsibilities from those assigned at the time of the change in control, or a change in such officer’s title or offices as in effect at the time of the change in control, or any removal of such officer from, or any failure to re-elect such officer to, any of such positions, except in connection with the termination of such officer’s employment by reason of disability or for cause; or
|
|
●
|
the relocation of the respective executive officer’s office to a location more than 60 miles from its location at the time of a change in control.
|
|
Name
|
Termination
without Cause ($)
|
Change in
Control ($)
|
||||||
|
Lucien Y. Bronicki
|
594,110 | 940,570 | ||||||
|
Yehudit Bronicki
|
719,959 | 1,144,009 | ||||||
|
Yoram Bronicki
|
198,824 | 691,768 | ||||||
|
Joseph Tenne
|
251,967 | 395,039 | ||||||
|
Nadav Amir
|
888,918 | 888,918 | ||||||
|
Zvi Reiss
|
499,958 | 499,958 | ||||||
|
Shimon Hatzir
|
427,253 | 427,253 | ||||||
|
Name
|
Fee Earned or
Paid in Cash ($)
|
Options Awards
($) (1) (2)
|
Total ($)
|
|||||||||
|
Gillon Beck
|
31,333 | 95,700 | 127,033 | |||||||||
|
Ami Boehm
|
34,333 | 95,700 | 130,033 | |||||||||
|
Dan Falk
|
78,000 | 42,750 | 120,750 | |||||||||
|
Robert F. Clarke
|
65,000 | 42,750 | 107,750 | |||||||||
|
David Granot
|
30,333 | 95,700 | 126,033 | |||||||||
|
Robert E. Joyal
|
32,333 | 95,700 | 128,033 | |||||||||
|
Roger W. Gale (3)
|
30,500 | - | 30,500 | |||||||||
|
David Wagener (3)
|
29,000 | - | 29,000 | |||||||||
|
|
(1)
|
Represents the grant date fair value in accordance with accounting guidance for stock compensation. For a discussion of the assumptions used in reaching this valuation, see Note 15 to our consolidated financial statements for the year ended December 31, 2012.
|
|
|
(2)
|
At fiscal year end, each non-management director held the following aggregate number of option awards: (i) Mr. Beck held options to purchase 15,000 shares; (ii) Mr. Boehm held options to purchase 15,000 shares; (iii) Mr. Granot held options to purchase 15,000 shares; (iv) Mr. Joyal held options to purchase 15,000 shares; (v) Mr. Falk held options to purchase 52,500 shares; and (vi) Mr. Clarke held options to purchase 52,500 shares.
|
|
|
(3)
|
Resigned as a director effective as of May 22, 2012.
|
|
|
The cash compensation of our non-employee directors is as follows:
|
|
|
1. Base annual retainer of $40,000 as fees related to their service on our Board of Directors.
|
|
|
2. Board meeting fees of $2,500 for each in-person meeting attended; $500 for each telephonic meeting attended; and $1,000 for telephonic participation in an in-person meeting.
|
|
|
3. Committee meeting fees of $1,500 for each in-person meeting attended and $500 for each telephonic meeting attended.
|
|
|
4. Any non-employee director who also serves as Chair of the Audit Committee receives an annual retainer of $7,500. Chairs of our other committees do not receive an annual retainer.
|
|
|
6. We promptly reimburse all directors for transportation and lodging expenses actually incurred to attend meetings of our Board of Directors or committees.
|
|
|
●
|
FIMI ENRG Limited Partnership, a newly formed Israeli limited partnership (the “Israeli Fund”).
|
|
|
●
|
FIMI ENRG L.P., a newly formed Delaware limited partnership (the “Foreign Fund”).
|
|
|
●
|
FIMI Opportunity IV, L.P., a limited partnership formed under the laws of the state of Delaware and FIMI Israel Opportunity IV, Limited Partnership, a limited partnership formed under the laws of Israel, both of which control the Israeli Fund and the Foreign Fund.
|
|
|
●
|
Share Purchase Agreement dated as of March 16, 2012 among (i) Bronicki Investments and (ii) the Foreign Fund and the Israeli Fund (collectively, the “Buyers”), which is described below (the “Bronicki Investments Sale Agreement”).
|
|
|
●
|
Shareholder Rights Agreement among (i) Bronicki Investments and (ii) the Buyers, which is described below, (the “Bronicki Investments FIMI Shareholder Agreement”).
|
|
|
●
|
a call option (exercisable during the two-month period following the fifth anniversary of the closing of the Bronicki Investments Sale Agreement) for the Buyers to purchase up to 9 million shares (less the number of shares otherwise sold by Bronicki Investments prior to the option exercise).
|
|
|
●
|
a right for the Buyers to receive for no additional consideration up to 2 million shares if certain post-closing financial tests are not satisfied.
|
|
|
●
|
A right of Bronicki Investments to assign to the Buyers the balance of its loan up to a maximum amount of NIS 183 million against a transfer to the Buyers of 9 million shares (representing a price of NIS 20.33 per share).
|
|
●
|
voting and transfers of the ordinary shares of our parent held by Bronicki Investments and the Buyers;
|
|
|
●
|
the composition of the board of directors of our parent and its active subsidiaries (including us and our active subsidiaries); and
|
|
|
●
|
agreements concerning various corporate policies and governance matters relating to our parent and its subsidiaries, to the extent subject to a vote of our parent’s shareholders.
|
|
|
●
|
subject to any applicable law and fiduciary duties, use their reasonable efforts to cause an equal number of designees of Bronicki Investments and the Buyers to be elected or appointed to our Board and to the boards of all active subsidiaries of our parent (including our subsidiaries). In the case of our Board, the Buyers and Bronicki Investments each have the right to designate four members. The number of directors that Bronicki Investments and the Buyers may designate is subject to staged adjustments if either Buyers or Bronicki Investments or both cease to own specified minimum amounts of our parent’s ordinary shares, within various ranges specified in the Bronicki Investments FIMI Shareholder Agreement.
|
|
|
●
|
subject to any applicable law, use their best efforts to cause (subject to continued holding of certain minimum amounts of our parent’s ordinary shares):
|
|
|
○
|
the continued service of Yehudit Bronicki as our Chief Executive Officer and of Yoram Bronicki as our President and Chief Operations Officer, in each case for a service period set forth in the Bronicki Investments FIMI Shareholder Agreement. If either Yehudit Bronicki or Yoram Bronicki is unable to fulfill these positions, Bronicki Investments is entitled to appoint to the applicable position another designee.
|
|
|
○
|
the appointment of FIMI’s designee to serve as our Chairman of the Board for a service period set forth in the Bronicki Investments FIMI Shareholder Agreement.
|
|
|
○
|
after the expiration of the service periods referred to above, the nomination of Bronicki Investments’s designee as our Chief Executive Officer or Chairman of the Board (as Bronicki Investments may decide in its sole discretion), and the appointment of FIMI’s designee as our Chairman of the Board (if Bronicki Investments’ designee serves as Chief Executive Officer) or our Chief Executive Officer (if Bronicki Investments’ designee serves as Chairman of the Board).
|
|
2012
|
2011
|
|||||||
|
Audit Fees
(1)
|
$ | 1,767,000 | $ | 1,509,000 | ||||
|
Audit-Related Fees
(2)
|
$ | 18,100 | $ | 38,000 | ||||
|
Tax Fees
(3)
|
$ | 91,200 | $ | 295,200 | ||||
|
All Other Fees
(4)
|
$ | 5,200 | $ | 5,200 | ||||
|
Total:
|
$ | 1,881,500 | $ | 1,847,400 | ||||
|
|
(1)
|
Audit Fees represent the aggregate fees billed for the audits of the annual financial statements and the Company’s internal control over financial reporting; for review of the financial statements included in the Company’s Form 10-Q filings; for the audits and reviews of certain of our subsidiaries; and for services that are normally provided by the independent registered public accounting firm in connection with statutory and regulatory filings.
|
|
|
(2)
|
Audit-Related Fees represent the aggregate fees billed for services related to the performance of the audit or review of our financial statements and are not reported under paragraph (1) above.
|
|
|
(3)
|
Tax Fees represent the aggregate fees billed for international tax compliance, tax advice, and tax planning services.
|
|
|
(4)
|
All Other Fees represent annual software license fees.
|
|
By order of the Board of Directors,
/s/ YEHUDIT BRONICKI
Yehudit Bronicki
Chief Executive Officer
|
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE ELECTION OF DIRECTORS AND "FOR" PROPOSAL 2.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENVELOPE PROVIDED. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE
x
|
|||||||
| 1. | Election of Directors. | ||||||
| FOR | AGAINST | ABSTAIN | |||||
| Gillon Beck | o | o | o | ||||
| Dan Falk | o | o | o | ||||
| FOR | AGAINST | ABSTAIN | |||||
| 2. |
To ratify the selection of PricewaterhouseCoopers LLP as independent auditors of the Company for its fiscal year ending December 31, 2013.
|
o | o | o | |||
| 3. | In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting. | ||||||
| This proxy is solicited on behalf of the Board of Directors of the Company. This proxy, when properly executed, will be voted in accordance with the instructions given above. If no instructions are given, this proxy will be voted "FOR" the election of the Directors and "FOR" proposal 2. | |||||||
| To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method. | o | ||||||
| Signature of Stockholder | Date: | Signature of Stockholder | Date: |
|
Note:
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|